Recommendations for correct therapy with digoxin from twenty-five sources are reviewed. Some recommendations may be unsuitable for use with high bioavailability tablets; some are accompanied by insufficient data relating to factors affecting both the response to digoxin and its handling by the body. Guidelines based on pharmacokinetic and pharmacodynamic principles are suggested to help decide optimal digoxin treatment schedules in the presence and absence of non-cardiac disease.